|
1
|
Ljungberg B, Campbell SC, Choi HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim DY, Karam JA and Wood CG: Role of
metastasectomy for metastatic renal cell carcinoma in the era of
targeted therapy. World J Urol. 32:631–642. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ridge CA, Pua BB and Madoff DC:
Epidemiology and staging of renal cell carcinoma. Semin Intervent
Radiol. 31:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ratain MJ, Eisen T, Stadler WM, Flaherty
KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, et
al: Phase II placebo-controlled randomized discontinuation trial of
sorafenib in patients with metastatic renal cell carcinoma. J Clin
Oncol. 24:2505–2512. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zustovich F, Lombardi G, Pastorelli D,
Farina P, Bianco MD, De Zorzi L, Palma MD, Nicoletto O and Zagonel
V: Clinical experience and critical evaluation of the role of
sorafenib in renal cell carcinoma. Open Access J Urol. 3:69–82.
2011.PubMed/NCBI
|
|
6
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al; TARGET Study Group. Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bianchi L, Rossi L, Tomao F, Papa A,
Zoratto F and Tomao S: Thyroid dysfunction and tyrosine kinase
inhibitors in renal cell carcinoma. Endocr Relat Cancer.
20:R233–R245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chiarugi P and Giannoni E: Anoikis: A
necessary death program for anchorage-dependent cells. Biochem
Pharmacol. 76:1352–1364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong X and Rescorla FJ: Cell surface
adhesion molecules and adhesion-initiated signaling: Understanding
of anoikis resistance mechanisms and therapeutic opportunities.
Cell Signal. 24:393–401. 2012. View Article : Google Scholar
|
|
10
|
Simpson CD, Anyiwe K and Schimmer AD:
Anoikis resistance and tumor metastasis. Cancer Lett. 272:177–185.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jenning S, Pham T, Ireland SK, Ruoslahti E
and Biliran H: Bit1 in anoikis resistance and tumor metastasis.
Cancer Lett. 333:147–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bouillez A, Gnemmi V, Gaudelot K, Hémon B,
Ringot B, Pottier N, Glowacki F, Butruille C, Cauffiez C, Hamdane
M, et al: MUC1-C nuclear localization drives invasiveness of renal
cancer cells through a sheddase/gamma secretase dependent pathway.
Oncotarget. 5:754–763. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sakamoto S, Schwarze S and Kyprianou N:
Anoikis disruption of focal adhesion-Akt signaling impairs renal
cell carcinoma. Eur Urol. 59:734–744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stoilov P, Castren E and Stamm S: Analysis
of the human TrkB gene genomic organization reveals novel TrkB
isoforms, unusual gene length, and splicing mechanism. Biochem
Biophys Res Commun. 290:1054–1065. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Glass DJ, Nye SH, Hantzopoulos P, Macchi
MJ, Squinto SP, Goldfarb M and Yancopoulos GD: TrkB mediates
BDNF/NT-3-dependent survival and proliferation in fibroblasts
lacking the low affinity NGF receptor. Cell. 66:405–413. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Douma S, Van Laar T, Zevenhoven J,
Meuwissen R, Van Garderen E and Peeper DS: Suppression of anoikis
and induction of metastasis by the neurotrophic receptor TrkB.
Nature. 430:1034–1039. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thiele CJ, Li Z and McKee AE: On Trk - the
TrkB signal transduction pathway is an increasingly important
target in cancer biology. Clin Cancer Res. 15:5962–5967. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lam CT, Yang ZF, Lau CK, Tam KH, Fan ST
and Poon RT: Brain-derived neurotrophic factor promotes
tumorigenesis via induction of neovascularization: implication in
hepatocellular carcinoma. Clin Cancer Res. 17:3123–3133. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sinkevicius KW, Kriegel C, Bellaria KJ,
Lee J, Lau AN, Leeman KT, Zhou P, Beede AM, Fillmore CM, Caswell D,
et al: Neurotrophin receptor TrkB promotes lung adenocarcinoma
metastasis. Proc Natl Acad Sci USA. 111:10299–10304. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fujikawa H, Tanaka K, Toiyama Y, Saigusa
S, Inoue Y, Uchida K and Kusunoki M: High TrkB expression levels
are associated with poor prognosis and EMT induction in colorectal
cancer cells. J Gastroenterol. 47:775–784. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sclabas GM, Fujioka S, Schmidt C, Li Z,
Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, et al:
Overexpression of tropomysin-related kinase B in metastatic human
pancreatic cancer cells. Clin Cancer Res. 11:440–449.
2005.PubMed/NCBI
|
|
22
|
Mawji IA, Simpson CD, Hurren R, Gronda M,
Williams MA, Filmus J, Jonkman J, Da Costa RS, Wilson BC, Thomas
MP, et al: Critical role for Fas-associated death domain-like
interleukin-1-converting enzyme-like inhibitory protein in anoikis
resistance and distant tumor formation. J Natl Cancer Inst.
99:811–822. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Geiger TR and Peeper DS: The neurotrophic
receptor TrkB in anoikis resistance and metastasis: A perspective.
Cancer Res. 65:7033–7036. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liotta LA and Kohn E: Anoikis: Cancer and
the homeless cell. Nature. 430:973–974. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong KK, Engelman JA and Cantley LC:
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet
Dev. 20:87–90. 2010. View Article : Google Scholar :
|
|
27
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Frisch SM and Screaton RA: Anoikis
mechanisms. Curr Opin Cell Biol. 13:555–562. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shih YW, Shieh JM, Wu PF, Lee YC, Chen YZ
and Chiang TA: Alpha-tomatine inactivates PI3K/Akt and ERK
signaling pathways in human lung adenocarcinoma A549 cells: effect
on metastasis. Food Chem Toxicol. 47:1985–1995. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wongpankam E, Chunhacha P, Pongrakhananon
V, Sritularak B and Chanvorachote P: Artonin E mediates MCL1
down-regulation and sensitizes lung cancer cells to anoikis.
Anticancer Res. 32:5343–5351. 2012.PubMed/NCBI
|
|
31
|
Klein R, Nanduri V, Jing SA, Lamballe F,
Tapley P, Bryant S, Cordon-Cardo C, Jones KR, Reichardt LF and
Barbacid M: The trkB tyrosine protein kinase is a receptor for
brain-derived neurotrophic factor and neurotrophin-3. Cell.
66:395–403. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pearse RN, Swendeman SL, Li Y, Rafii D and
Hempstead BL: A neurotrophin axis in myeloma: TrkB and BDNF promote
tumor-cell survival. Blood. 105:4429–4436. 2005. View Article : Google Scholar
|
|
33
|
Yu X, Liu L, Cai B, He Y and Wan X:
Suppression of anoikis by the neurotrophic receptor TrkB in human
ovarian cancer. Cancer Sci. 99:543–552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smit MA and Peeper DS: Zeb1 is required
for TrkB-induced epithelial-mesenchymal transition, anoikis
resistance and metastasis. Oncogene. 30:3735–3744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ramnath N and Adjei A: Inhibitors of Raf
kinase and MEK signaling. Update Cancer Ther. 2:111–118. 2007.
View Article : Google Scholar
|
|
36
|
Kim MJ, Kim DE, Jeong IG, Choi J, Jang S,
Lee JH, Ro S, Hwang JJ and Kim CS: HDAC inhibitors synergize
antiproliferative effect of sorafenib in renal cell carcinoma
cells. Anticancer Res. 32:3161–3168. 2012.PubMed/NCBI
|
|
37
|
Srikanthan A, Ethier JL, Ocana A, Seruga
B, Krzyzanowska MK and Amir E: Cardiovascular toxicity of
multi-tyrosine kinase inhibitors in advanced solid tumors: A
population-based observational study. PLoS One. 10:e01227352015.
View Article : Google Scholar : PubMed/NCBI
|
